Stockreport

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab) [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF Immuneering Corporation Thu, February 6, 2025 at 1:00 PM GMT+1 5 min read In This Article IMRX Immuneering Corporation - Immuneering plans to evaluate IMM-1 [Read more]